Senator Investment Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Senator Investment Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-408,000	Closed	-$50.6M	–	42
2018 Q4	$50.6M	Sell	408,000 -617,000	-60%	-$91.5M	1.41%	26
2018 Q3	$172M	Sell	1,025,000 -5,000	-0.5%	-$860K	2.22%	23
2018 Q2	$177M	Sell	1,030,000 -468,295	-31%	-$76.5M	1.76%	24
2018 Q1	$226M	Buy	1,498,295 +100,000	+7%	+$14.7M	2.69%	14
2017 Q4	$188M	Buy	1,398,295 +98,295	+8%	+$13.6M	2.02%	21
2017 Q3	$190M	Buy	1,300,000 +300,000	+30%	+$45.4M	2.53%	16
2017 Q2	$156M	Buy	1,000,000 +250,000	+33%	+$38.2M	1.75%	23
2017 Q1	$109M	Buy	+750,000	New	+$97.7M	1.34%	29

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Senator Investment Group's JAZZ Position: Q1 2019 in Review

Senator Investment Group sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 408,000 shares — an estimated $50.6M sold.

Senator Investment Group first reported a position in JAZZ in Q1 2017 and held it in 8 quarters. The position peaked at $226M in Q1 2018. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

Senator Investment Group reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Senator Investment Group sold 408,000 Jazz Pharmaceuticals shares in Q1 2019, an estimated $50.6M.
Senator Investment Group first reported a position in Jazz Pharmaceuticals in Q1 2017 and held it in 8 quarters.
Senator Investment Group's Jazz Pharmaceuticals position peaked at $226M in Q1 2018.
427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Senator Investment Group's 13F filing for Q1 2019, filed 15 May 2019.